Phase II BLOSSOM Trial Osimertinib in LMD from EGFR+ NSCLC by Sehhoon Park et al.

Jarushka Naidoo shared a post on X:

“Phase II BLOSSOM Trial Osimertinib in LMD (leptomeningeal dx) from EGFR+ NSCLC:

•  80 mg daily
•  73 patients, 64 evaluable for ORR
• mOS 15.6m, LMD ORR 51.6%
• Mainly g1-2 tox

Osimertinib is efficacious in this challenging subset.”

Read further
Source: Jarushka Naidoo/X

Dr. Jarushka Naidoo is a thoracic oncologist at the Beaumont Hospital Dublin (Ireland), a Professor in RCSI, and an Adjunct Professor of Oncology at Johns Hopkins University. She currently serves as the national lung cancer lead for Cancer Trials Ireland. She serves on several international guideline panels including ASCO and SITC (Society of Immunotherapy for Cancer), and is an experienced clinical trialist- having developed and completed several investigator-initiated, industry-funded, and cooperative group clinical trials.